Linaclotide - Irritable bowel syndrome with constipation (IBS-C)
You are here : Home > Formulary Search > Linaclotide - Irritable bowel syndrome with constipation (IBS-C)
I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.
Documentation
- No records returned.
PAD Profile
ChemicalSubstance :
Linaclotide
Indication :
Irritable bowel syndrome with constipation (IBS-C)
Group Name :
Keywords :
IBS-C
Brand Names Include :
Constella
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
0
Other Indications
Below are listed other indications that Linaclotide is used to treat.
- No records returned.
Other Drugs
Below are listed other drugs that are used to treat Irritable bowel syndrome with constipation (IBS-C).
- No records returned.
Committee Recommendations (1)
Two key trials suggest that linaclotide may be an effective treatment, when compared with placebo. However, assessing linaclotide's place in therapy in the NHS is problematic because of the absence of active comparator studies. Local gastroenterologists support the use of Linaclotide in a small group of difficult to treat patients. They believe that if it is available for prescribing in primary care, it may reduce the number of referrals to secondary care and colonoscopies. GP colleagues noted that IBS is often diagnosed by exclusion and that they sometimes refer if they feel the diagnosis may not be certain, so they feel that the reduction in secondary care referrals and costs may not be as great as anticipated. They did acknowledge that where a diagnosis is clear/confirmed, it would be useful to have access to this drug without having to refer patients. A treatment pathway is attached for information